A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma (Q43761409)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5837861

A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma (English)

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5837861

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Pieter Sonneveld

3

object named as

Pieter Sonneveld

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5837861

Robert Z Orlowski

11

object named as

Robert Z Orlowski

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5837861

9

object named as

Sonja Zweegman

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5837861

author name string

Peter M Voorhees

1

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5837861

Robert F Manges

2

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5837861

Sundar Jagannath

4

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5837861

George Somlo

5

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5837861

Amrita Krishnan

6

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5837861

Suzanne Lentzsch

7

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5837861

Richard C Frank

8

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5837861

Pierre W Wijermans

10

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5837861

Britte Kranenburg

12

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5837861

Brett Hall

13

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5837861

Tineke Casneuf

14

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5837861

Xiang Qin

15

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5837861

Helgi van de Velde

16

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5837861

Hong Xie

17

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5837861

Sheeba K Thomas

18

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5837861

language of work or name

0 references

publication date

25 February 2013

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5837861

British Journal of Haematology

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5837861

161

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5837861

357-366

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5837861

3

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5837861

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837861

14 June 2018

Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837861

14 June 2018

A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837861

14 June 2018

Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837861

14 June 2018

Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837861

14 June 2018

A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837861

14 June 2018

Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837861

14 June 2018

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837861

14 June 2018

Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837861

14 June 2018

IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837861

14 June 2018

BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837861

14 June 2018

The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837861

14 June 2018

Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837861

14 June 2018

Interferon-alpha protects myeloma cell lines from dexamethasone-induced apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837861

14 June 2018

Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837861

14 June 2018

The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837861

14 June 2018

Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837861

14 June 2018

Interleukin-6 prevents dexamethasone-induced myeloma cell death.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837861

14 June 2018

Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837861

14 June 2018

Response patterns of purified myeloma cells to hematopoietic growth factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837861

14 June 2018

International uniform response criteria for multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837861

16 June 2018

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837861

16 June 2018

Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837861

15 August 2018

Clinical course of patients with relapsed multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837861

15 August 2018

The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837861

15 August 2018

Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5837861

15 August 2018

Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12266

21 January 2018

Interleukin-6 inhibits apoptosis of malignant plasma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/23432640

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

IFN-alpha is a survival factor for human myeloma cells and reduces dexamethasone-induced apoptosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23432640

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The gp 130 family cytokines IL-6, LIF and OSM but not IL-11 can reverse the anti-proliferative effect of dexamethasone on human myeloma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/23432640

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

1 reference

https://pubmed.ncbi.nlm.nih.gov/23432640

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinically relevant end points and new drug approvals for myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23432640

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism

1 reference

https://pubmed.ncbi.nlm.nih.gov/23432640

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/BJH.12266

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5837861

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5837861

1 reference

Europe PubMed Central

13 June 2018

http://europepmc.org/abstract/PMC/5837861

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43761409&oldid=2103111777"